What does PAQUES PHARMA do?

PAQUES PHARMA is a pharmacy in Profondeville. Private Limited, started on 24 June 2005, 1 establishment.

What is the address of PAQUES PHARMA?

The registered office of PAQUES PHARMA is located at Chaussée de Dinant 11, 5170 Profondeville.

Is PAQUES PHARMA still active?

Yes. According to the CBE (30 October 2026) PAQUES PHARMA is active, legal situation “Normale toestand”, started on 24 June 2005.

Is PAQUES PHARMA registered on Peppol?

Yes, PAQUES PHARMA is registered on the Peppol network with ID 0208:0874668893.

What is the enterprise number of PAQUES PHARMA?

The enterprise number of PAQUES PHARMA is BE0874668893.

When was PAQUES PHARMA founded?

PAQUES PHARMA was founded on 24 June 2005.

Who are the directors of PAQUES PHARMA?

According to the 2025 annual accounts, the directors of PAQUES PHARMA are: Philippe Paques.

Is PAQUES PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 June 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PAQUES PHARMA make in 2025?

PAQUES PHARMA posted a profit after taxes of € 45,293 in financial year 2025.

What is the revenue of PAQUES PHARMA?

As a small company, PAQUES PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 295,378.

How much does an employee at PAQUES PHARMA earn?

The average wage cost per full-time employee at PAQUES PHARMA was € 59,900 in 2025: staff costs of € 125,764 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PAQUES PHARMA have?

According to the 2025 annual accounts, PAQUES PHARMA has 2.1 full-time equivalents (FTE).

PAQUES PHARMA (Private Limited) - Profondeville

Dossier PAQUES PHARMA, printed on 30 October 2026 from databakkes.be/en/0874668893/paques-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 49 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PAQUES PHARMA from Profondeville, company number BE0874668893, closed financial year 2025 with a result of € 45,293 after tax. For that financial year PAQUES PHARMA recorded a gross margin of € 295,378 and equity of € 309,887. Compared with financial year 2024, the result moved from € 48,957 to € 45,293. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What it is worth Healthy

€ 309,887

▼ 44% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 45,293

▼ 7% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 137,859

▼ 5% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 289,833 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 125,764

▲ 4% vs 2024

€ 59,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 34,479

▼ 27% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 47,789

▼ 43% vs 2024

€ 25,954 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 31,668

▲ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,421

▼ 10% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 315,141 Gross margin 2022: € 315,141 First fiscal year in the series	€ 302,862 Gross margin 2023: € 302,862 ▼ 4% vs 2022 (€ 315,141) Unfavourable step	€ 296,550 Gross margin 2024: € 296,550 ▼ 2% vs 2023 (€ 302,862) Unfavourable step	€ 295,378 Gross margin 2025: € 295,378 Unchanged (€ 296,550) Unfavourable step
Profit after taxes	€ 105,834 Profit after taxes 2022: € 105,834 First fiscal year in the series	€ 72,416 Profit after taxes 2023: € 72,416 ▼ 32% vs 2022 (€ 105,834) Unfavourable step	€ 48,957 Profit after taxes 2024: € 48,957 ▼ 32% vs 2023 (€ 72,416) Unfavourable step	€ 45,293 Profit after taxes 2025: € 45,293 ▼ 7% vs 2024 (€ 48,957) Unfavourable step	▼ 7%
Equity	€ 515,687 Equity 2022: € 515,687 First fiscal year in the series	€ 562,303 Equity 2023: € 562,303 ▲ 9% vs 2022 (€ 515,687) Favourable step	€ 554,426 Equity 2024: € 554,426 ▼ 1% vs 2023 (€ 562,303) Unfavourable step	€ 309,887 Equity 2025: € 309,887 ▼ 44% vs 2024 (€ 554,426) Unfavourable step	▼ 44%
Total debts	€ 405,990 Total debts 2022: € 405,990 First fiscal year in the series	€ 332,043 Total debts 2023: € 332,043 ▼ 18% vs 2022 (€ 405,990) Favourable step	€ 289,769 Total debts 2024: € 289,769 ▼ 13% vs 2023 (€ 332,043) Favourable step	€ 487,787 Total debts 2025: € 487,787 ▲ 68% vs 2024 (€ 289,769) Unfavourable step	▲ 68%
Cash	€ 254,655 Cash 2022: € 254,655 First fiscal year in the series	€ 83,603 Cash 2023: € 83,603 ▼ 67% vs 2022 (€ 254,655) Unfavourable step	€ 145,460 Cash 2024: € 145,460 ▲ 74% vs 2023 (€ 83,603) Favourable step	€ 137,859 Cash 2025: € 137,859 ▼ 5% vs 2024 (€ 145,460) Unfavourable step	▼ 5%
Land & buildings	€ 129,916 Land & buildings 2022: € 129,916 First fiscal year in the series	€ 103,484 Land & buildings 2023: € 103,484 ▼ 20% vs 2022 (€ 129,916) Unchanged	€ 77,052 Land & buildings 2024: € 77,052 ▼ 26% vs 2023 (€ 103,484) Unchanged	€ 58,919 Land & buildings 2025: € 58,919 ▼ 24% vs 2024 (€ 77,052) Unchanged	▼ 24%
Retained profit	€ 509,487 Retained profit 2022: € 509,487 First fiscal year in the series	€ 556,103 Retained profit 2023: € 556,103 ▲ 9% vs 2022 (€ 509,487) Favourable step	€ 548,226 Retained profit 2024: € 548,226 ▼ 1% vs 2023 (€ 556,103) Unfavourable step	€ 303,687 Retained profit 2025: € 303,687 ▼ 45% vs 2024 (€ 548,226) Unfavourable step	▼ 45%
Dividend	€ 15,800 Dividend 2022: € 15,800 First fiscal year in the series	€ 25,800 Dividend 2023: € 25,800 ▲ 63% vs 2022 (€ 15,800) Unchanged	€ 56,833 Dividend 2024: € 56,833 ▲ 120% vs 2023 (€ 25,800) Unchanged	€ 289,833 Dividend 2025: € 289,833 ▲ € 233,000 vs 2024 (€ 56,833) Unchanged	▲ € 233,000
Bank debt	€ 184,342 Bank debt 2022: € 184,342 First fiscal year in the series	€ 134,519 Bank debt 2023: € 134,519 ▼ 27% vs 2022 (€ 184,342) Favourable step	€ 84,017 Bank debt 2024: € 84,017 ▼ 38% vs 2023 (€ 134,519) Favourable step	€ 47,789 Bank debt 2025: € 47,789 ▼ 43% vs 2024 (€ 84,017) Favourable step	▼ 43%
Balance sheet total	€ 921,676 Balance sheet total 2022: € 921,676 First fiscal year in the series	€ 894,346 Balance sheet total 2023: € 894,346 ▼ 3% vs 2022 (€ 921,676) Unchanged	€ 844,196 Balance sheet total 2024: € 844,196 ▼ 6% vs 2023 (€ 894,346) Unchanged	€ 797,673 Balance sheet total 2025: € 797,673 ▼ 6% vs 2024 (€ 844,196) Unchanged	▼ 6%
Employees (FTE)	1.8 Employees (FTE) 2022: 1.8 First fiscal year in the series	2.1 Employees (FTE) 2023: 2.1 ▲ 0.3 vs 2022 (1.8) Unchanged	2.1 Employees (FTE) 2024: 2.1 Unchanged (2.1) Unchanged	2.1 Employees (FTE) 2025: 2.1 Unchanged (2.1) Unchanged

Key figures of PAQUES PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PAQUES PHARMA?

What happened at PAQUES PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 28, 2026 New annual accounts for financial year 2025: profit of € 45,293 (▼ 7% vs 2024). Source: NBB ↗
Jun 24, 2005 Start of the company according to the CBE. KBO
2005 Philippe Paques became a director. NBB
Jun 13, 2005 New establishment in Profondeville. KBO

In short

From € 105,834 profit in 2022 to € 45,293 profit in 2025.

Paid € 111,244 in corporate taxes since 2022.

Best year ever: 2022, with € 105,834 profit.

On average € 140,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Philippe Paques

PAQUES PHARMA

Behind PAQUES PHARMA is Philippe Paques.

Directors

According to the 2025 annual accounts

Philippe Paques

Administrator-manager

since 2005

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Dinant 11

5170 Profondeville

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PHARMA VAL

€ 31,027 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0874.668.893

VAT number

BE 0874.668.893

Registered office

Chaussée de Dinant 11, 5170 Profondeville

Names & denominations

PAQUES PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

24 June 2005

Peppol

Active · Active since 17 Feb 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

PAQUES PHARMA

Warning lights

Financials

What happened to PAQUES PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions